Turkey [electronic resource] : Pharmaceutical Sector Analysis. / Yusuf Celik.

By: Celik, YusufContributor(s): Celik, Yusuf | Seiter, AndreasMaterial type: TextTextSeries: Other Health Study | World Bank e-LibraryPublication details: Washington, D.C. : The World Bank, 2008Subject(s): Antibiotics | Bribery | Burden of Disease | Clinical Trials | Consumer Protection | Corruption | Counterfeit Drugs | Crime | Decision Making | Doctors | Employment | Expenditures | Fraud | Generic Drugs | Gross Domestic Product | Health Insurance | Health Law | Health Monitoring & Evaluation | Health Outcomes | Health Policy | Health Systems Development & Reform | Health, Nutrition and Population | Heroin | Hospitals | Law and Development | Leukemia | Marketing | Nurses | Nutrition | Patents | Pharmaceutical Industry | Pharmaceuticals | Pharmaceuticals & Pharmacoeconomics | Pharmacies | Physicians | Private Health Insurance | Public Health | Public Hospitals | Surgery | WorkersOnline resources: Click here to access online Abstract: Pharmaceuticals are essential to achieve health outcomes, but are at the same time a major cost factor in every health system. From a patient perspective, access to pharmaceuticals is a proxy for the functioning of the health system. With increasing economic strength, patients become more demanding with regard to access to modern, sophisticated drugs and providers become more aggressive in marketing those drugs. This paper reflects the situation in the pharmaceutical sector in Turkey, identifies critical issues, and discusses policy options based on current trends and the overall policy objectives of the Turkish government. This paper is structured as follows: chapter one gives introduction; chapter two gives overall policy objectives in the pharmaceutical sector in Turkey; chapter three presents institutional and regulatory framework; chapter four presents reimbursement rules; chapter five focuses on governance issues in the pharmaceutical sector; chapter six gives market overview; chapter seven gives payment for pharmaceuticals in Turkey; chapter eight presents prescribing practices - rational use of medicines; and chapter nine gives conclusions and way forward.
Tags from this library: No tags from this library for this title. Log in to add tags.
    Average rating: 0.0 (0 votes)
No physical items for this record

Pharmaceuticals are essential to achieve health outcomes, but are at the same time a major cost factor in every health system. From a patient perspective, access to pharmaceuticals is a proxy for the functioning of the health system. With increasing economic strength, patients become more demanding with regard to access to modern, sophisticated drugs and providers become more aggressive in marketing those drugs. This paper reflects the situation in the pharmaceutical sector in Turkey, identifies critical issues, and discusses policy options based on current trends and the overall policy objectives of the Turkish government. This paper is structured as follows: chapter one gives introduction; chapter two gives overall policy objectives in the pharmaceutical sector in Turkey; chapter three presents institutional and regulatory framework; chapter four presents reimbursement rules; chapter five focuses on governance issues in the pharmaceutical sector; chapter six gives market overview; chapter seven gives payment for pharmaceuticals in Turkey; chapter eight presents prescribing practices - rational use of medicines; and chapter nine gives conclusions and way forward.

There are no comments on this title.

to post a comment.

Powered by Koha